Axsome Therapeutics (NASDAQ: AXSM) executives highlighted growth across its commercial portfolio, an

Axsome Therapeutics NASDAQ: AXSM executives said the company is seeing accelerating prescription gro

Axsome Therapeutics NASDAQ: AXSM executives highlighted growth across its commercial portfolio, an e

Bank of America Corp DE bought a new stake in Axsome Therapeutics, Inc. (NASDAQ: AXSM) during the se

Axsome Therapeutics' revenue is growing at a good clip. The company has a deep pipeline as well.

Axsome Therapeutics is seeing significant revenue growth as its central nervous system portfolio gai

Piper Sandler analyst David Amsellem reiterates Axsome Therapeutics (NASDAQ:AXSM) with a Overweig

Axsome Therapeutics is generating rapid revenue growth through its expanding portfolio of commercial

Axsome Therapeutics has launched exciting new drugs over the past year, and they are delivering grow

NEW YORK, Sept. 17, 2026 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmace

Axsome Therapeutics, Inc. (AXSM) Presents at H.C. Wainwright 28th Annual Global Investment Conferenc

Axsome Therapeutics, Inc. (AXSM) Presents at Morgan Stanley 24th Annual Global Healthcare Conference

One company is scaling revenue rapidly but burning cash; the other is pioneering gene therapy with m

Axsome Therapeutics, Inc. (AXSM) Presents at 12th Annual Cantor Fitzgerald Global Healthcare Confere

Axsome Therapeutics has transitioned into a commercial-stage entity with rapidly growing revenue fro

Axsome Therapeutics, Inc. (AXSM) Presents at Wells Fargo 21st Annual Healthcare Conference Transcrip

Axsome (AXSM) reported earnings 30 days ago. What's next for the stock?

NEW YORK, Sept. 02, 2026 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmace

AXSM begins dosing in the phase III SUMMIT study investigating AXS-05 for treating smoking cessation

HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Axsome Therapeutics (NASDAQ:AXSM) w

Axsome Therapeutics, Inc. (NASDAQ:AXSM), a biopharmaceutical company leading a new era in the treatm

NEW YORK, Aug. 31, 2026 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceu

Amgen is a diversified pharmaceutical giant with high net margins. It reported nearly $8.1 billion i

Axsome Therapeutics is performing well as it continues to expand its approved portfolio. The company

Axsome Therapeutics (NASDAQ:AXSM) has outperformed the market over the past 5 years by 46.84% on an

Axsome Therapeutics (NASDAQ:AXSM) has outperformed the market over the past 10 years by 26.64% on an

Mizuho analyst Graig Suvannavejh maintains Axsome Therapeutics (NASDAQ:AXSM) with a Outperform an

Morgan Stanley analyst Sean Laaman maintains Axsome Therapeutics (NASDAQ:AXSM) with a Equal-Weigh

RBC Capital analyst Leonid Timashev maintains Axsome Therapeutics (NASDAQ:AXSM) with a Outperform

Axsome Therapeutics (NASDAQ:AXSM) reported Q2 losses of 99 cents per share and sales of $218.4 milli

Guggenheim analyst Yatin Suneja maintains Axsome Therapeutics (NASDAQ:AXSM) with a Buy and raises

Wells Fargo analyst Benjamin Burnett maintains Axsome Therapeutics (NASDAQ:AXSM) with a Overweigh

Wall Street analysts changed outlook on top names. See complete view of all changes, upgrades, downg

Needham analyst Ami Fadia maintains Axsome Therapeutics (NASDAQ:AXSM) with a Buy and raises the p

Axsome Therapeutics (NASDAQ:AXSM) reported quarterly losses of $(0.99) per share which missed the an

Mizuho analyst Graig Suvannavejh maintains Axsome Therapeutics (NASDAQ:AXSM) with a Outperform an

Wall Street analysts upgraded Fortinet, Goldman Sachs, Adaptive Biotechnologies, and Five Below, wit

Top Wall Street analysts change outlook on top stocks. For analyst rating changes, see https://www.b

BMO Capital analyst Malcolm Hoffman initiates coverage on Axsome Therapeutics (NASDAQ:AXSM) with

HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Axsome Therapeutics (NASDAQ:AXSM) w

Axsome Therapeutics, Inc. (NASDAQ:AXSM), a biopharmaceutical company leading a new era in the treatm

This whale alert can help traders discover the next big trading opportunities. Whales are entities w

HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Axsome Therapeutics (NASDAQ:AXSM) w

RBC Capital analyst Leonid Timashev maintains Axsome Therapeutics (NASDAQ:AXSM) with a Outperform

FOCUS-2 (Forward Treatment of Attention Deficit and Hyperactivity Using Solriamfetol) is a Phase 3,

Health officials explored restricting specific antidepressants among SSRI drugs-sources

Global Business Travel Group Inc (GBTG), a NYSE-listed company, saw its stock rise 57% on Monday af

FDA clears Axsome's Auvelity for Alzheimer's agitation, backed by Phase 3 data, expanding it